Prolotherapy Injection Using Platelet-Rich Plasma for Patients Suffering from Chronic Sacroiliac Pain

Prolotherapy Injection Using Platelet-Rich Plasma for Patients Suffering from Chronic Sacroiliac Pain - Platelet-Rich Plasma for Sacroiliac Pain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000056603

Enrollment

Registered

2025-01-13

Start date

2022-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Completed

Interventions

Platelet-rich plasma Dextrose 25%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Target patients were those in whom the sacroiliac joint was the prominent source of low back pain.

Exclusion criteria

Exclusion criteria: Patients under the age of 30 years and those over the age of 90 years Local infection in the sacroiliac joint region Coagulation disorder Poorly controlled diabetes mellitus Autoimmune disorders Mental and psychiatric disorders Lost to follow-up

Design outcomes

Primary

Measure	Time frame
The numerical pain scale (NPS) is the primary target outcome, which will be measures as baseline during the first interview, 1.5 months, 3 months and 6 months after injection.	—

Secondary

Measure	Time frame
Oswestry Disability Index (ODI), rescue analgesic consumption, and the economic cost.	—

Countries

Africa

Contacts

Public ContactMahmoud Al-Abd

Faculty of Medicine, Menoufia University Department of Anesthesiology, Intensive care and Pain management

mahmoud.kawy.abd@gmail.com+201098223176

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026